Medroxyprogesterone acetate injectable vials recalled for lack of sterility assurance
Sun Pharmaceutical is recalling 26,892 vials of medroxyprogesterone acetate injectable suspension (150 mg/mL) distributed nationwide due to lack of assurance of sterility. The affected lots expire between January and June 2023.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II injectable drug recall with documented sterility deficiency. Although no illnesses or injuries have been reported, non-sterile injectable medications pose significant risk of serious infection, fitting the rubric criterion of 'risk-of-harm products where injury has not yet been reported.'
Plain-English summary
Sun Pharmaceutical Industries Inc is recalling medroxyprogesterone Acetate Injectable Suspension, USP (150 mg/mL) distributed nationwide. The recall involves 26,892 vials packaged in 25-count cartons with NDC number 16714-090-40. Three production lots are affected: HAC2074A (expiration 06/2023), HAC0163B (expiration 01/2023), and HAC1741A (expiration 04/2023).
The recall was initiated due to lack of assurance of sterility. Sterility is a critical requirement for injectable medications to prevent serious infections and other adverse health effects.
Healthcare providers and patients who may have received injections from the affected lots should consult their healthcare provider. The product is manufactured by Sun Pharmaceutical Industries Ltd. in Halol, Gujarat, India and distributed by Sun Pharmaceutical Industries, Inc. in Cranbury, New Jersey.
The recalled product
- Product
- medroxyPROGESTERone Acetate Injectable Suspension, USP, 25 x 1 mL Single-Dose Vial, 150 mg/mL, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Ltd., Halol Baroda Highway, Halol-389 350, Gujarat India
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Injectable Suspension
- Hazard
- sterility-failure
- non-sterile-drug
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot#: HAC2074A
- Exp Date 06/2023
- HAC0163B
- Exp Date 01/2023 & HAC1741A
- Exp Date 04/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27